

JANUARY 26, 2009

...To Meet Your
Research Needs
In Diabetes,
Endocrinology,
and Diabetes
Complications...

TABLE OF CONTENTS

Renewal	1
Metabolism Meeting	2
Inflammation Core	3
P&F Announcement	4



Please remember to cite the DERC Grant in all papers that utilize DERC Cores or are supported by the Pilot and Feasibility Awards:

"Our research utilized Core (or Research) support from the UCSD/UCLA NIDDK Diabetes and Endocrinology Research Center P30 DK063491."

NEWS FLASH

The UCSD/UCLA DERC is RENEWED for Five Years



We are pleased to announce that our UCSD/UCLA Diabetes Endocrinology Research Center competitive renewal application was successful and that the grant was approved and funded for a new five-year period. We are currently in the first year of this new project period, and this Newsletter outlines some of the new developments and alignments of the current Center grant. Most importantly, the original PI, Dr. Willa Hsueh, left UCLA a year ago to take a new position in Houston. As a result, Dr. Jerrold Olefsky has now assumed responsibility as PI of the overall Center grant for its current five-year project period. Since the overhead rates of the two Institutions are comparable, this is mainly an administrative issue with no real budgetary impact and simply affects where bills are sent and where the checks are issued. On a more substantive subject, the new Center grant has all of the original Cores and two programs. In addition, as part of our continuation grant, we received funding for a new Core headed by Peter Tontonoz, called the "Inflammation Core".

Core A: Transgenic and Knockout Mouse Core, Director: Pamela Mellon

Core B: Mouse Phenotyping Core, Director: Rajendra Tangirala

Core C: Transcriptional Genomics Core, Director: Christopher Glass

Core D: Human Genetics Core, Director: Jerome Rotter

Core E: Inflammation Core, Director: Peter Tontonoz

NEW in 2008, SEE PAGE 3

Pilot & Feasibility Program, Director: Pinchas Cohen

2009 P&F Announcement, SEE PAGE 4

Academic Enrichment Program, Director: Jerrold Olefsky

Meeting Announcement: SEE PAGE 2

All of the original services offered by the DERC cores are still provided and these are now supplemented by a new list of services and resources offered through the Inflammation Core.

Sincerely yours,

Jerrold Olefsky, M.D., UCSD
DERC P.I.





NEW!
Listserv for DERC Members

Send announcements, communications, requests, etc., to your DERC colleagues!

DERC-L@UCSD.EDU

If you are receiving this newsletter directly, you are already subscribed! If you would like to subscribe, please send an email to mellonadmin@ucsd.edu. This is a moderated listserv, so messages will be prescreened such that only relevant and important messages will reach you.

NEW WEBSITE currently under construction!
<http://DERC.UCSD.EDU>

Contact information for DERC Cores and Programs:

DERC PI/Director:

Jerrold Olefsky
(858) 534-6651
jolefsky@ucsd.edu

Administration:

Betsy Hansen
(858) 534-6651
ejhansen@ucsd.edu

Pilot & Feasibility Program

Pinchas Cohen, M.D.
(310) 206-5844
hassy@mednet.ucla.edu

Transgenic and Knockout Mouse CORE:

<http://cancer.ucsd.edu/tgm/>
Pamela Mellon, Ph.D.
Core Director

Core Contacts:

Jun Zhao
Transgenic Mice Contact
858-822-3270
tg@ad.ucsd.edu

Ella Kothari
Gene Targeting (Embryonic Stem Cells and Blastocyst Injection) Contact
858-534-3178
stemc@ad.ucsd.edu

Heather Oakley
Embryo Cryopreservation
858-822-2108
cryo@ad.ucsd.edu

MEETING ANNOUNCEMENT

Clinical Investigation Institute/Nature Medicine Bench to Bedside: Metabolism

October 8-10, 2009

As part of our Enrichment activities, the DERC will help host a scientific meeting co-sponsored by Nature Medicine and UCSD next Fall in La Jolla. This Nature Medicine meeting is focused on Diabetes and Metabolism and begins the evening of October 8th, ending at Noon at Saturday October 10th. On Saturday afternoon, (October 10th), the DERC will put on its own scientific presentations, based on the work of P&F recipients. The program for this meeting is outstanding (see attached) and all DERC members, including all P&F recipients, are encouraged to attend the full meeting starting Thursday evening. The Western region DERCs (Baylor, UCSD/UCLA, University of Colorado, and University of Washington) have organized into a subgroup and through the Regional DERC Director's committee, we have already arranged for P&F recipients from the other Western Centers to attend this meeting. Speakers Include:

- Michael Brown** (U Texas)
- Helen Hobbs** (U Texas)
- Gokhan Hotamisligil** (Harvard)
- Peter Libby** (Harvard)
- Michael Karin** (UCSD)
- Steve Shoelson** (Joslin Diabetes Center)
- Paresh Dandona** (SUNY Buffalo)
- Gerry Shulman** (Yale)
- Ira Goldberg** (Columbia)
- Phil Scherer** (U Texas)
- Barbara Kahn** (Harvard)
- Chris Newgard** (Duke)
- Tony Lam** (Toronto)
- Zofia Zukowska** (Georgetown)
- Daniel Drucker** (Toronto)
- David Cummings** (U Wash)
- Francesco Rubino** (Cornell Medical Center-NYC)



Hilton La Jolla Torrey Pines

10950 North Torrey Pines Road, La Jolla, California

http://www1.hilton.com/en_US/hi/hotel/SANTPHH-Hilton-La-Jolla-Torrey-Pines-California/index.do

Page 3

Mouse Phenotyping CORE:

Rajendra Tangirala, PhD

Core Director

Pinchas Cohen, MD

Core Co-Director

Andrea Hevener, PhD

Core Co-Director

David Hwang, PhD

Core Co-Director

Core Contacts:

Binrong Liu

310-825-8499

bliu@mednet.ucla.edu

Diana Becerra/Jason Kim

310-794-6612

dbecerra@mednet.ucla.edu

Transcriptional Genomics CORE:

<http://www.microarrays.ucsd.edu>

Chris Glass, Ph.D.

Core Director

Gary Hardiman, Ph.D.

Core Co-Director

BIOGEM Core Facility

Nicholas Webster, Ph.D.

Core Co-Director

VA Genechip Core

Core Contacts:

BIOGEM Core

Agilent and Illumina Arrays

Solexa Sequencing

Colleen Ludka

(858) 822-4231

cludka@ucsd.edu

Genechip Core

Affymetrix Arrays

454 Sequencing

Jorge Valencia

(858) 552-8585 x7100

genechip@vapop.ucsd.edu

Human Genetics CORE:

Jerome Rotter, M.D.

Core Director

Leslie Raffel, M.D.

Core Co-Director

Xiuqing Guo, Ph.D.

Core Co-Director

Kent D. Taylor, Ph.D.

Core Co-Director

Core Contact:

Cynthia Hernandez, R.N.

Core Contact

(310) 423-1457

Cynthia.Hernandez@cshs.org

Inflammation CORE:

Peter Tontonoz, M.D., Ph.D.

Core Director

Rajendra Tangirala, PhD

Core Co-Director

Core Contact:

Rima Boyadjian

310-206-4622

rboyadjian@mednet.ucla.edu

The Inflammation CORE CORE Director: Peter Tontonoz, M.D., Ph.D.

Professor of Pathology and Laboratory Medicine

The Inflammation Core is an outgrowth of the interests of our DERC membership in mechanisms of inflammation that play roles in the development and progression of both metabolic and cardiovascular diseases. The objective of this Core is to provide state-of-the-art assays and techniques to investigators focusing on the role of inflammation in the settings of obesity, insulin resistance and diabetes. The Inflammation Core will aid DERC investigations by providing:

1. Standardized, accurate, precise and quality-controlled analyses.
2. Consistent, high-quality human monocyte preparations.
3. High-throughput profiling of nuclear receptor expression.
4. Consultation on available assays, experimental design and data interpretation.
5. Instruction on how to perform Core assays at user request.
6. Contacts to foster collaborations in the role of inflammation in diabetes and its complications.



DERC Inflammation Core services

Service	Non DERC Members	DERC Members
Luminex protein assay: Human, Mouse, Rat Cytokine, Chemokine, Adipokine & CVD1	\$300 per assay	\$150 per assay
Luminex mRNA assays	\$300 per assay	\$150 per assay
HMW/LMW Human adiponectin	\$350	\$175
Nuclear receptor profiling	\$150	\$75

Multiplex assays offered through the Core are listed below:

- **Human Adipokine:** Adiponectin (total), PAI-1, Resistin
- **Mouse Adipokine:** Il-6, Insulin, Leptin, MCP-1, PAI-1, Resistin, TNF- α
- **Rat Adipokine:** IL-1 β , Il-6, Insulin, Leptin, MCP-1, PAI-1, TNF- α
- **Human CVD1:** MMP-9, MPO, PAI-1 (total), sE-selectin, sICAM-1, sVCAM-1
- **Mouse CVD1:** MMP-9, PAI-1 (total), sE-selectin, sICAM-1, sVCAM-1
- **Human Cytokines/Chemokines:** IL-1 α , IL-1 β , IL-1R α , IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17, EGF, Eotaxin, Fractalkine, G-CSF, GM-CSF, IFN γ , IP-10, MCP-1, MIP-1 α , MIP-1 β , RANTES, sCD40L, TGF α , TNF α , VEGF
- **Mouse Cytokine / Chemokine:** IL-1 α , IL-1 β , IL-2, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17, G-CSF, GM-CSF, IFN γ , IP-10, KC, MCP-1, MIP-1 α , RANTES, TNF α
- **Rat Cytokines/Chemokines:** IL-1 α , IL-1 β , IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 (p70), IL-13, IL-17, IL-18, Eotaxin, G-CSF, GM-CSF, GRO/KC, IFN γ , IP-10, Leptin, MCP-1, MIP-1 α , RANTES, TNF α , VEGF

Core Contact: Rima Boyadjian, 310-206-4622, rboyadjian@mednet.ucla.edu

DERC P&F**Timetable for applications:**

Grants should be emailed to Dr. Pinchas Cohen at: hassy@mednet.ucla.edu.
Grants are due on March 6th 2009
 with an anticipated start date on May 1st 2009.

Contact information for Pilot and Feasibility Program:

Pinchas Cohen, M.D.
 (310) 206-5844
hassy@mednet.ucla.edu

2008 P&F AWARDEES

Laura Cobb, Ph.D., Assistant Professor, Division of Pediatric Endocrinology, Mattel Children's Hospital at UCLA

SHLPs: a novel family of peptides regulating glucose metabolism and insulin sensitivity

Robyn Cunard, M.D., Assistant Professor, UCSD Medicine/Nephrology, VA San Diego Healthcare System, La Jolla

Podocyte TRB3 in Diabetic Nephropathy

Aleksey V. Matveyenko, Ph.D., Assistant Professor, Larry L. Hillblom Islet Research Center, UCLA David Geffen School of Medicine

Elucidation of Mechanism(s) by Which Circadian Rhythm Disturbances Increase the Risk for Development of Type 2 diabetes

Varykina G. Thackray, Ph.D., Assistant Professor, Reproductive Medicine, UCSD

The Role of the Forkhead Transcription Factor, FoxO1 in the Pituitary Gonadotrope: A Link Between Metabolism and Fertility?

DERC P&F 2009 Grant ANNOUNCEMENTApplications DUE **March 6th 2009****Pilot and feasibility projects in Endocrinology and Diabetes**

As part of the recently renewed UCSD/UCLA DERC grant, a mechanism to fund innovative new projects that will explore the feasibility of novel testable concepts and enhance the endocrine/diabetes research scope within the institutions is again available. The Pilot and Feasibility grant program is putting out a request for applications that will support 4-5 grantees at approximately \$30,000-\$40,000 per year. A special emphasis on promoting promising junior faculty involved with diabetes research is key to the UCSD/UCLA P&F mission. It is expected that P&F studies will generate preliminary data that will be used by these investigators in diabetes/endocrinology-related RO1 applications in the years following their award.

P&F grant format

A strict requirement for the grant format will be implemented. Failure to meet this requirement will lead to an administrative disqualification of the proposal. The P&F grant applications should include:

- (a) A face page with the title of the grant, the name, email, academic title, and department and institution of the PI, the names of any additional personnel and collaborators and a 200 word abstract.
- (b) Biosketches for the PI and other key personnel.
- (c) The scientific proposal (5-page limit).
- (d) References.

The entire grant **must be submitted** as a single emailed pdf file less than 2 megabyte in size. If the grant includes high-resolution images, these must be reduced to meet the size requirement. Failure to provide a single pdf file or a file that is too big will result in disqualification. No budget is required, but the scope of the work should be appropriate for 1-year project and the funds cannot be used for the PI salary.

Eligibility

All eligible investigators must have faculty appointments at UCLA or UCSD and be independent investigators. To be eligible for a P&F grant you need to be eligible to submit an RO1 as a PI at the end of the grant period. A joint appointment at an affiliated institution is allowed. Investigators eligible for pilot and feasibility funding generally will be expected to fall into three categories:

- (Category 1) New investigators without current or past non-mentored NIH research support as a principal investigator (current or past support from other sources being modest).
- (Category 2) Established investigators with no previous work in diabetes that wish to apply their expertise to a problem in this area.
- (Category 3) Established investigators in diabetes/endocrinology research who propose testing innovative ideas that represent clear departure from ongoing research interests.

Interactions with other DERC components

It is expected that junior faculty will be able to rely on the advice and support of a senior DERC investigators and will have a priority access to DERC Cores, including an opportunity to discuss their projects in depth with the core directors in order to receive maximum benefits from their services. Similarly, investigators with no previous experience in diabetes/endocrinology research will be expected to have a DERC collaborator. P&F grantees will be encouraged and expected to utilize DERC core resources.

Final report and presentation at the annual retreat

A report on each pilot and feasibility study conducted will be requested from investigators at the end of the study period and an update will be requested yearly for four years after the completion of the award. These brief reports will contain professional career status at the time of the award and at the time of the report; an overview of the project including its significance and salient results; a list of resulting publications; and peer-reviewed subsequent funding in the same or related areas. Funded P&F investigators will be expected to attend the annual DERC retreat as well as in a meeting of Regional P&F awardees, and present the results of their work in the year immediately following their award. Travel to these meetings will be charged to the individual P&F awards. **ALL PAPERS MUST CITE P30 DK063491**

Notification procedure:

After approval of the funding decisions by the DERC executive committee, funded and unfunded investigators will be notified and, when appropriate, a brief summary of the reviews will be sent to them by email (not a detailed critique).

FULL ANNOUNCEMENT ALSO ATTACHED AS A PDF